BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Tang C, Li L, Mo T, Na J, Qian Z, Fan D, Sun X, Yao M, Pan L, Huang Y, Zhong L. Oncolytic viral vectors in the era of diversified cancer therapy: from preclinical to clinical. Clin Transl Oncol 2022. [PMID: 35612653 DOI: 10.1007/s12094-022-02830-x] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
Number Citing Articles
1 Pal K, Sheth RA. Engineering the Tumor Immune Microenvironment through Minimally Invasive Interventions. Cancers (Basel) 2022;15. [PMID: 36612192 DOI: 10.3390/cancers15010196] [Reference Citation Analysis]
2 Russo E, Spallarossa A, Tasso B, Villa C, Brullo C. Nanotechnology for Pediatric Retinoblastoma Therapy. Pharmaceuticals 2022;15:1087. [DOI: 10.3390/ph15091087] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
3 Ji Q, Wu Y, Albers A, Fang M, Qian X. Strategies for Advanced Oncolytic Virotherapy: Current Technology Innovations and Clinical Approaches. Pharmaceutics 2022;14:1811. [DOI: 10.3390/pharmaceutics14091811] [Cited by in F6Publishing: 1] [Reference Citation Analysis]